中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 7
Jul.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(7): 1609-1616

Efficacy and safety of microwave ablation combined with systemic chemotherapy in treatment of recurrent intrahepatic cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2023.07.015
  • 1a.

    Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

  • 1b.

    Department of Hepatobiliary Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

  • 2.

    Fourth Department of Oncology, The Second People's Hospital of Neijiang, Neijiang, Sichuan 641000, China

Research funding:

Major National Science and Technology Projects (2018zx09303-014);

Sichuan Provincial Health Commission (18PJ194)

More Information
  • Corresponding author: JIANG Ou, jiangou866@163.com (ORCID: 0000-0002-6615-8068)
  • Received Date: 2022-11-03
  • Accepted Date: 2022-12-18
  • Published Date: 2023-07-20
    Abstract
  •   Objective  To investigate the efficacy and safety of microwave ablation (MWA) combined with chemotherapy versus MWA alone in the treatment of recurrent intrahepatic cholangiocarcinoma (RICC).  Methods  A retrospective cohort study was conducted among the patients with RICC who received MWA+chemotherapy or MWA in The Second People's Hospital of Neijiang and The Affiliated Hospital of Southwest Medical University from January 2014 to March 2021, and their clinicopathological data were collected. The independent samples t-test was used for comparison of continuous data, and the chi-square test and the Fisher's exact test were used for comparison of categorical data. The Kaplan-Meier method was used to calculate progression-free survival (PFS) and overall survival (OS), and the Log-rank test was used for comparison of survival differences. Univariate and multivariate Cox proportional-hazards regression model analyses were used to investigate the risk factors for survival and prognosis.  Results  A total of 106 patients with RIC were enrolled, among whom there were 55 patients in the MWA+chemotherapy group and 51 in the MWA group. By the end of follow-up, the MWA+chemotherapy group had a median PFS of 15.0 months (95% confidence interval [CI]: 14.5-15.5), and the MWA group had a median PFS of 13.4 months (95%CI: 11.6-15.2), with a significant difference between the two groups (χ2=9.624, P=0.002). The MWA+chemotherapy group had a median OS of 21.0 months (95%CI: 20.0-21.8), and the MWA group had a median OS of 18.0 months (95%CI: 16.3-19.7), with a significant difference between the two groups (χ2=12.784, P < 0.001). The Cox regression analysis showed that tumor diameter (PFS: hazard ratio [HR]=0.425, 95%CI: 0.208-0.868, P=0.019; OS: HR=0.299, 95%CI: 0.121-0.739, P=0.009), time to recurrence (PFS: HR=7.064, 95%CI: 3.612-13.618, P < 0.001; OS: HR=2.341, 95%CI: 1.072-5.113, P=0.033), and combined chemotherapy (PFS: HR=0.138, 95%CI: 0.069-0.276, P < 0.001; OS: HR=0.175, 95%CI: 0.081-0.380, P < 0.001) were independent influencing factors for PFS and OS in patients with RICC. As for the common adverse reactions, there were no significant differences in the incidence rates of all adverse reactions except hematological toxicity (χ2=12.524, P < 0.001).  Conclusion  Compared with MWA alone, MWA combined with chemotherapy can improve the prognosis of RICC and prolong PFS and OS, with safe and controllable side effects. Patients with tumor diameter > 5 cm, time to recurrence < 1 year, and absence of systemic chemotherapy tend to have a poor prognosis.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    KHAN SA, DAVIDSON BR, GOLDIN RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update[J]. Gut, 2012, 61(12): 1657-1669. DOI: 10.1136/gutjnl-2011-301748.
    [2]
    DING XY, SUN W, SHEN YJ, et al. Efficacy and safety of lenvatinib combined with sintilimab as the second-line therapy for intrahepatic cholangiocarcinoma[J]. J Clin Hepatol, 2022, 38(8): 1813-1818. DOI: 10.3969/j.issn.1001-5256.2022.08.018.

    丁晓燕, 孙巍, 申燕军, 等. 仑伐替尼联合信迪利单抗二线治疗肝内胆管癌的效果和安全性[J]. 临床肝胆病杂志, 2022, 38(8): 1813-1818. DOI: 10.3969/j.issn.1001-5256.2022.08.018.
    [3]
    CLOYD JM, EJAZ A, PAWLIK TM. The Landmark series: Intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2020, 27(8): 2859-2865. DOI: 10.1245/s10434-020-08621-4.
    [4]
    DOUSSOT A, GONEN M, WIGGERS JK, et al. Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: Preoperative and postoperative prognostic models[J]. J Am Coll Surg, 2016, 223(3): 493-505. e2. DOI: 10.1016/j.jamcollsurg.2016.05.019.
    [5]
    WRIGHT GP, PERKINS S, JONES H, et al. Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: A comparison of surgical resection with intra-arterial therapies[J]. Ann Surg Oncol, 2018, 25(1): 83-90. DOI: 10.1245/s10434-017-6110-1.
    [6]
    BARTSCH F, PASCHOLD M, BAUMGART J, et al. Surgical resection for recurrent intrahepatic cholangiocarcinoma[J]. World J Surg, 2019, 43(4): 1105-1116. DOI: 10.1007/s00268-018-04876-x.
    [7]
    ZHANG XF, BEAL EW, BAGANTE F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent[J]. Br J Surg, 2018, 105(7): 848-856. DOI: 10.1002/bjs.10676.
    [8]
    LI M, LU YY, DONG JH, et al. Clinical effect of transcatheter arterial chemoembolization combined with microwave ablation in treatment of advanced primary liver cancer[J]. J Clin Hepatol, 2020, 36(12): 2720-2724. DOI: 10.3969/j.issn.1001-5256.2020.12.016.

    李猛, 陆荫英, 董景辉, 等. 经肝动脉化疗栓塞术联合微波消融治疗中晚期原发性肝癌的效果分析[J]. 临床肝胆病杂志, 2020, 36(12): 2720-2724. DOI: 10.3969/j.issn.1001-5256.2020.12.016.
    [9]
    HAN Y, SHAO N, XI X, et al. Use of microwave ablation in the treatment of patients with multiple primary malignant tumors[J]. Thorac Cancer, 2017, 8(4): 365-371. DOI: 10.1111/1759-7714.12445.
    [10]
    XU C, LI L, XU W, et al. Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results[J]. Int J Hyperthermia, 2019, 36(1): 351-358. DOI: 10.1080/02656736.2019.1571247.
    [11]
    SPOLVERATO G, KIM Y, ALEXANDRESCU S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection[J]. Ann Surg Oncol, 2016, 23(1): 235-243. DOI: 10.1245/s10434-015-4642-9.
    [12]
    YUAN ZB, FANG HB, FENG QK, et al. Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy: A retrospective study[J]. World J Gastroenterol, 2022, 28(15): 1574-1587. DOI: 10.3748/wjg.v28.i15.1574.
    [13]
    VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281. DOI: 10.1056/NEJMoa0908721.
    [14]
    MIURA JT, JOHNSTON FM, TSAI S, et al. Chemotherapy for surgically resected intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22(11): 3716-3723. DOI: 10.1245/s10434-015-4501-8.
    [15]
    BENSON AB, D'ANGELICA MI, ABBOTT DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5): 541-565. DOI: 10.6004/jnccn.2021.0022.
    [16]
    SPOLVERATO G, EJAZ A, KIM Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis[J]. J Am Coll Surg, 2014, 219(4): 664-675. DOI: 10.1016/j.jamcollsurg.2014.03.062.
    [17]
    EISENHAUER EA, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026.
    [18]
    MAVROS MN, ECONOMOPOULOS KP, ALEXIOU VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: Systematic review and meta-analysis[J]. JAMA Surg, 2014, 149(6): 565-574. DOI: 10.1001/jamasurg.2013.5137.
    [19]
    LURJE G, BEDNARSCH J, RODERBURG C, et al. Intrahepatic cholangiocarcinoma - current perspectives and treatment algorithm[J]. Chirurg, 2018, 89(11): 858-864. DOI: 10.1007/s00104-018-0718-y.
    [20]
    TAKAHASHI Y, EBATA T, YOKOYAMA Y, et al. Surgery for recurrent biliary tract cancer: A single-center experience with 74 consecutive resections[J]. Ann Surg, 2015, 262(1): 121-129. DOI: 10.1097/SLA.0000000000000827.
    [21]
    YANG HI, SHERMAN M, SU J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection[J]. J Clin Oncol, 2010, 28(14): 2437-2444. DOI: 10.1200/JCO.2009.27.4456.
    [22]
    KIM GH, KIM PH, KIM JH, et al. Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis[J]. Eur Radiol, 2022, 32(2): 1205-1215. DOI: 10.1007/s00330-021-08216-x.
    [23]
    SHROFF RT, KENNEDY EB, BACHINI M, et al. Adjuvant Therapy for resected biliary tract cancer: ASCO clinical practice guideline[J]. J Clin Oncol, 2019, 37(12): 1015-1027. DOI: 10.1200/JCO.18.02178.
    [24]
    DÍAZ-GONZÁLEZÁ, VILANA R, BIANCHI L, et al. Thermal ablation for intrahepatic cholangiocarcinoma in cirrhosis: Safety and efficacy in non-surgical patients[J]. J Vasc Interv Radiol, 2020, 31(5): 710-719. DOI: 10.1016/j.jvir.2019.06.014.
    [25]
    HAN K, KO HK, KIM KW, et al. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis[J]. J Vasc Interv Radiol, 2015, 26(7): 943-948. DOI: 10.1016/j.jvir.2015.02.024.
    [26]
    CARRAFIELLO G, LAGANÀ D, COTTA E, et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience[J]. Cardiovasc Intervent Radiol, 2010, 33(4): 835-839. DOI: 10.1007/s00270-010-9849-3.
    [27]
    SHI Q, CHEN D, ZHOU C, et al. Drug-eluting beads versus lipiodol transarterial chemoembolization for the treatment of hypovascular hepatocellular carcinoma: A single-center retrospective study[J]. Cancer Manag Res, 2020, 12: 5461-5468. DOI: 10.2147/CMAR.S255960.
    [28]
    FENG R, TAO ZG, XU HY, et al. The short-term curative effect of the callisphere drug embolization microsphere in the treatment of malignant tumor of the liver[J]. J Clin Radiol, 2019, 38(6): 1107-1111. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFS201906040.htm

    冯锐, 陶志刚, 徐后云, 等. CalliSpheres载药栓塞微球治疗肝脏乏血供恶性肿瘤短期疗效分析[J]. 临床放射学杂志, 2019, 38(6): 1107-1111. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFS201906040.htm
    [29]
    CHEN X, DU J, HUANG J, et al. Neoadjuvant and adjuvant therapy in intrahepatic cholangiocarcinoma[J]. J Clin Transl Hepatol, 2022, 10(3): 553-563. DOI: 10.14218/JCTH.2021.00250.
    [30]
    STEIN A, ARNOLD D, BRIDGEWATER J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase Ⅲ trial[J]. BMC Cancer, 2015, 15: 564. DOI: 10.1186/s12885-015-1498-0.
    [31]
    EDELINE J, BENABDELGHANI M, BERTAUT A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase Ⅲ Study[J]. J Clin Oncol, 2019, 37(8): 658-667. DOI: 10.1200/JCO.18.00050.
    [32]
    MAZZAFERRO V, GORGEN A, ROAYAIE S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 72(2): 364-377. DOI: 10.1016/j.jhep.2019.11.020.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (286) PDF downloads(23) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return